Figure 5From: Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors Figure 5. Hematological toxicity of 131 I-labeled B-B4 mAb. Hematological toxicity was estimated by counting the leukocytes (A) and platelets (B) after treatment with increasing doses of 131I-labeled B-B4 mAb. All mice treated with 37 MBq died before day 14.Back to article page